Objectives. Differences in clinical manifestations of familial Mediterranean fever (FMF ) between different ethnic groups have been documented. The FMF gene was recently cloned and four missense mutations (Met694Val, Met680Ile, Val726Ala, and Met694Ile) that account for a large percentage of the patients were identified. The results of initial mutation studies have led to the hypothesis that phenotypic variation of the disease may be attributable to the existence of some of these mutations. The purpose of this study was to evaluate whether this phenotypic variation is associated with the existence of particular mutations in Turkish FMF patients living in Turkey.
Familial Mediterranean fever (FMF ) is a genetic disease 60% has been reported in Turks, 27% in Jews, and lower with autosomal recessive inheritance. The disease most rates in Armenians and Arabs [1, 4, 5, 7, 8] . commonly occurs in Jews, Turks, Armenians, and
In 1997, the International FMF Consortium and the Arabs. FMF is characterized by recurrent and selfFrench FMF Consortium independently cloned the gene limited attacks of fever accompanied by peritonitis, for the disease on the short arm of chromosome 16 and pleuritis, synovitis, or erysipelas-like erythema.
identified four missense mutations on FMF carrier chromoAmyloidosis is the most important complication of the somes [9, 10] . The French FMF Consortium reported disease that determines the prognosis [1] . Phenotypic that four disease-associated mutations (Met694Val, variation between different ethnic groups has already Met680Ile, Val726Ala and Met694Ile) accounted for been documented [1, 2] . Several authors have empha-85% of the carrier chromosomes in their study group sized that Turks have a severe disease with a relatively [10] . The results of these initial studies have led to the higher incidence of amyloidosis as compared with the hypothesis that phenotypic variation of the disease may other ethnic groups [3] [4] [5] [6] . The incidence of amyloidosis be attributable to the existence of particular mutations in patients with FMF appears to be markedly influenced [9, 10] . The Met694Val mutation is also known as the by ethnic background. In early reports, an incidence of Mediterranean mutation since it was demonstrated in FMF patients from different ethnic backgrounds including non-Ashkenazi Jewish, Turkish, Armenian, and from a single ancestral chromosome, which originated by the presence of amyloid depositions in renal biopsy probably more than 2000 yr ago [11] . The Met694Val specimens in all of them. The genetic data covering the mutation was found in 97% of the North African, 30% mutation results were kept by another investigator coded of the Iraqi Jewish, and about 25% of the Armenian for each patient as a blind trial to be evaluated later. carrier chromosomes [12, 13] . As this is the most common mutation in populations with a high incidence Mutation analysis of amyloidosis, the possible explanation was that the The four mutations (Met694Val, Met680Ile, Val726Ala, Met694Val homozygotes would be prone to the developand Met694Ile) were systematically investigated in the ment of amyloidosis [9, 13] . In contrast to the above patients. DNA was extracted from peripheral blood findings, the Val726Ala mutation was described in somelymphocytes according to standard procedures. what different ethnic groups, including Ashkenazi Jews, Mutation identification was performed according to Druzes, Armenians, and Iraqi Jews in which amyloidosis previously described techniques. Exon 10 of the gene is seen at lower frequencies. This suggested that the was amplified with the polymerase chain reaction (PCR) Val726Ala mutation might be protective for amyloidosis with specific forward 5∞-GAGGTGGAGGTT- [9, 13] . However, recently our group has shown that GGAGACAA-3∞ and reverse 5∞-TCCTCCTCTGAAATCthe development of amyloidosis is not prevented by the CATGG-3∞ primers [9] . For the identification of the presence of the Val726Ala mutation [14] . The mutations were assessed by amplifying the seen in Armenians was suggested to be associated with genomic DNA template with three sets of normal a milder phenotype of the disease and lower frequency and mutant-specific amplification refractory mutation of amyloidosis [7, 18] . These exciting data from the system (ARMS ) primers designed to selectively amplify literature encouraged us to gather a large amount of the normal or altered sequence of each of the FMF data on Turkish FMF patients to study the genotypegene mutations: Met694Val, Val726Ala and Met694Ile. phenotype correlation. In this respect, by this study we Each set of primers consisted of three oligointended to evaluate the existence of four mutations and nucleotides, their sequences were as follows: Metto correlate the phenotypic features with the co-existing 694Val common: 5∞-TATCATTGTTCTGGGCTC-3∞, type of mutation.
mutant: 5∞-TGGTACTCATTTTCCTTCAC-3∞, normal: 5∞-TGGTACTCATTTTCCTTCAT-3∞ [21].
Materials and methods
Val726Ala common: 5∞-TGGAGGTTGGAGACAAG-ACAGCATGGATCC-3∞, mutant 5∞-TGGGATCTGGThe ethics committee approved the study encompassing CTGTCACATTGTAAAAGGAGATGCTTCCTG-3∞, 238 Turkish FMF patients from 167 unrelated families.
normal: 5∞-TGGGATCTGGCTGTCACATTGTAAAInformed consent was obtained from each patient or AGGAGATGCTTCCTA-3∞ [21]. Met694Ile common: parent. Nevertheless, the study was limited to 167 index 5∞-TATCATTGTTCTGGGCTC-3∞, normal: 5∞-CTGcases to prevent the influence of background genes in GTACTCATTTTCCTTC-3∞, mutant: 5∞-CTGGTACTmultiplex families. The diagnosis of FMF was estab-CATTTTCCTTT-3∞ [10] . For the analysis of Val726Ala lished according to previously described criteria [19] .
both ARMS and restriction endonuclease (RE )/AluI As the patients had been referred from a number of methods were used. medical centres throughout Turkey, all of them were PCR amplification was performed in a final volume interviewed directly by one of the clinicians with idenof 100 ml containing 100 ng of purified genomic DNA, tical clinical forms. A questionnaire including the follow-0.2 U Taq polymerase (Promega) and its 10× PCR ing information: sex, age of onset, age at diagnosis, the buffer (containing 15 m MgCl 2 ), 0.2 m dNTP mix presence of fever, peritonitis, pleuritis, arthritis, erysip-(Promega) and 1 pmol of each primer. The PCR amplielas-like lesion, the severity score of the disease, the fication conditions were kept the same for all of the development of amyloidosis, and the presence of a ARMS tests and the reaction was carried out as follows: family history of FMF and amyloidosis, was developed.
heating of the reaction to 94°C for 5 min for denaturaThe severity score of the disease (manifested by an tion, followed by 35 cycles with denaturation at 94°C earlier age of onset, an increase in frequency and severity for 1 min, annealing at 60°C for 1 min and extension at of joint involvement, a higher incidence of erysipelas-72°C for 2 min, followed by 7 min final extension at like erythema and requirement of a higher dose of 72°C. The amplified products were separated by electrocolchicine to control symptoms) was calculated accordphoresis on a 2% agarose gel. Ethidium bromide staining ing to the previously described criteria [20] . Patients of the agarose gel was used to detect the amplified with amyloidosis presented with persistent proteinuria or nephrotic syndrome and the diagnosis was confirmed fragments [21] . compound heterozygotes with two of the four mutations. mutation, differences between the three groups for age Thirty-three (20%) patients had only a single mutation of onset, age at diagnosis and disease severity score were and no mutation was identified on either of the alleles evaluated using one-way ANOVA after log transformain four (2%). These results show that 88% of the studied tion. When there was a significant difference between chromosomes were carriers of the mutations and clinical the groups, Tukey's Honestly Significant Difference diagnosis of FMF was confirmed by molecular study in (HSD) test was used for multiple comparisons. For the 78% of the patients in our study group. Met680Ile mutation, differences between the three groups in the above parameters were evaluated by Genotype-phenotype correlation Kruskall-Wallis variance analysis. The results are
In order to demonstrate whether there is a mutationreported as mean ± standard deviation (..). For all specific difference in the phenotypic expression of the tests a two-tailed P value of <0.05 was considered as disease, the patients were pooled according to the pressignificant.
ence of the two mutations: Met694Val and Met680Ile, the former previously defined as severe and the latter Results as milder. For evaluation of the Met694Val mutation, 167 Clinical data patients were divided into three groups according to the Table 1 summarizes the phenotypic features of the presence of the Met694Val mutation on both of the patients. Eighty-four of the 167 patients were male and alleles (homozygotes), on only one allele (hetero-83 were female. The age of onset ranged from 1 month zygotes), and on none of the alleles. Twelve clinical to 40 yr with a mean of 6 yr. The common clinical parameters of the disease were compared between the features were abdominal pain and fever, followed by 41 homozygous and 91 compound heterozygous patients arthritis and chest pain. Four patients had protracted for the Met694Val mutation, and 35 patients who did arthritis, one of whom had been reported as an unusual not have this mutation ( Table 3 ). The age of onset was complication of FMF [22] . Renal biopsy revealed amylhigher in the homozygous patients as compared with oidosis in 25 (15%) patients.
the patients of the other groups (P < 0.05). No statistically significant differences were found between these Genetic data groups for the other phenotypic features, including the The mutation frequencies of the carrier chromosomes frequency of amyloidosis. are shown in Table 2 , Met694Val being the most Similarly, the patients were divided into three groups common mutation, found in 41% of the chromosomes according to the presence of the Met680Ile mutation studied. The Met694Ile mutation, which was exceedingly ( Table 4 ). The frequency of arthritis was significantly rare in other than Arabic FMF patients, was found in lower in the patients who were homozygous for the 17% of the carrier chromosomes in our patient populaMet680Ile mutation when compared with the other two groups. There were no statistically significant differences the patients without this mutation.
Age at onset (yr ± ..) 6.30 ± 6.85 Table 5 shows the frequencies of all observed genoAge at diagnosis (yr ± ..) 11.97 ± 9.61 types and the frequencies of amyloidosis in these geno- one of the three mutations [23] . Our data, which is essential to detect asymptomatic patients who are homozygous for the Met694Val mutation and treat them included 167 patients along with the above findings, confirm that these four mutations can be used to identify in order to prevent amyloidosis [15, 18] . However, none of the 83 patients from Israel showed the Met680Ile or the molecular defect in most Turkish FMF patients. However, it should be noted that we included only Met694Ile mutations. Moreover, 80 of them had the Met694Val mutation on at least one allele and 70 typical FMF patients in this study. Therefore, it would not be surprising if these four mutations accounted for patients were homozygotes for this mutation, including 12 with amyloidosis [13] . The data from the French a smaller percentage in a broader sample. This phenomenon was observed in the National Institutes of Health group included only three patients with amyloidosis, all were homozygous for the Met694Val mutation in their experience in which three mutations were found in 85% of FMF patients initially, yet 16 mutations are detected 109 Jewish FMF patients [15] . Recently three reports have supported these preliminary studies. Brik et al. in only 79% of the patients currently [11] . Since the disease is clearly autosomal recessive, our patients with [24] reported the mutation analysis of a total of 70 patients with FMF from mainly North African Jews only one mutation most probably have one of the other mutations that were not studied here. Similarly, four and Moslem Arabs. Although they found an association between severe disease and homozygosity of the patients who did not have the four mutations studied probably have other mutations because they have clasMet694Val mutation, their study did not include any patients with amyloidosis. In Shohat et al.'s [17] report, sical features of FMF.
Two preliminary studies from Israel and France have amyloidosis was present in 18 of 87 patients who were homozygous for the Met694Val mutation and two of 41 emphasized the importance of the Met694Val mutation. Their results indicate that Met694Val homozygotes genwho were compound heterozygous. They could not find a patient with amyloidosis without the Met694Val mutaerally do have more severe disease and a higher risk of developing amyloidosis than those who are not carriers tion. Livneh et al. [16 ] reported the mutation analysis of 178 non-Ashkenazi Jewish patients which included of this mutation [13, 15] . It was also suggested that it T 6. Mutation distribution in 25 patients with amyloidosis (a total of 50 alleles) 30 patients with amyloidosis. Twenty-seven of their patients with amyloidosis were homozygous for the Met694Val mutation. However, their report also included two patients who were homozygous for the Val726Ala mutation. In another recent report, the Met694Val mutation was found to be uncommon in an Ashkenazi Jewish population in which amyloidosis was also uncommon [11] . Based on these reports, one should expect to observe a high frequency of the Met694Val mutation with an association of amyloidosis in Turkish patients, since Turks have severe disease and a high frequency of amyloidosis. However, we could not find any evidence that supports this claim for Turkish FMF patients. It should be noted that the FMF patients in this study had a broad spectrum of mutation combinations, which might reflect the inter-cultural interactions of ancient ethnic groups that lived in Anatolia. Moreover, certain environmental factors might play roles in the development of amyloidosis. Our results show that the presence or homozygosity of the Met694Val mutation is associated with neither a severe form of the disease nor the risk of developing amyloidosis in this Turkish FMF population living in Turkey.
Previous reports indicate that the Armenian population tends to have a less severe disease and a low incidence of amyloidosis that may be due to the high occurrence of the Met680Ile mutation in this ethnic group [7, 18] . When we compared the clinical features, only the frequency of arthritis was found to be lower in the patients with homozygous Met680Ile mutation. Interestingly, none of our 11 patients with homozygous Met680Ile mutation had a history of arthritis during their febrile attacks. The frequency of amyloidosis did not differ with homozygosity, heterozygosity or the absence of this mutation.
The relationship between FMF and amyloidosis is still obscure. It is known that the development of amyloidosis is not a complication of a more severe disease, but rather an associated condition, because there are some patients who present with amyloidosis with very mild or no inflammatory symptoms. In our study, considerable variations in the phenotypic features of the disease were noted in all groups, including the patients who were homozygous for the Met694Val mutation. Unlike the French and Israeli experience, our data indicate that specific FMF mutations are not the sole determinants of disease severity and the development of amyloidosis. Furthermore, we also noted that 25 patients with amyloidosis showed all four missense mutations studied. Two recent reports from the USA and the UK zygous for the Met694Val mutation [25] . In the study 25-31. from the UK, nine patients out of 27 had amyloidosis, 
